pulmonx.com (LUNG) - Cash per Single Share

Cash reserves per share demonstrate management's efficiency in optimizing expenses and expanding sales. Pulmonx Corporation (LUNG) innovative valves ensure leadership in emphysema therapy, having earned the full trust of physicians. The value of 1.22 serves as the base parameter, confirming the business's high macro-stability due to consistent insurance coverage and the absence of pronounced cyclicality in demand for medical care.
Comprehensive metric breakdowns and analytics for Pulmonx Corp (LUNG)

This metric is calculated by dividing the company's total cash balance by the number of shares outstanding. This figure determines the liquid reserve per share, creating a defensive buffer against market volatility. For Pulmonx Corporation (LUNG), this is a critical resource given the risks of declining insurance reimbursements and competition from low-cost COPD therapy methods. An excess of idle capital may hinder development. By analyzing the amount of free cash per share, an investor assesses the financial stability of the business.